Liege, Belgium, 14 January 2022 - 07:30 CET - Mithra (Euronext Brussels: MITRA), a company
dedicated to Women's Health, today announces positive efficacy top-line results from Donesta® Phase
3 pivotal "E4 Comfort" clinical trials for the treatment of Vasomotor Symptoms (VMS) in postmenopausal women. Donesta® is Mithra's next generation orally-administrated estetrol (E4)-based
hormone therapy product candidate.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 14 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 January 2022 06:41:04 UTC.